Adjunctive Bright Light Therapy in Patients With Bipolar Depression and Eveningness

Bipolar Depression Clinical Trial

Official title:

A Randomized Placebo-controlled Trial for Adjunctive Bright Light Therapy in Patients With Bipolar Depression and Eveningness

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05357313
• Other study ID #: 2020.676T
• Secondary ID: 14111502
• Status: Recruiting
• Phase: N/A
• Start date: June 2, 2022
• Est. completion date: December 2024

Study information

• Verified date: February 2024
• Source: Chinese University of Hong Kong
• Contact: Joey WY Chan
• Phone: +852 39197647
• Email: joeywychan[@]cuhk.edu.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized placebo-controlled trial to examine the efficacy of six-week bright light therapy as adjunctive treatment for patient with bipolar depression and eveningness.

Description:

This randomized placebo-controlled trial aims to evaluate the efficacy of adjunctive BLT in addition to their maintenance treatment in reducing depressive symptoms. The second aim of the study is to explore the effects of BLT on sleep-wake changes and the sleep disturbances.

Method: Each eligible participant will be randomized to either i) bright light therapy (BLT) or ii) inactive negative ion generator (placebo) treatment for 30-minutes daily at their habitual wake time for a total of six weeks. Participants will be evaluated at baseline, 2nd, 4th and 6th week for depression and insomnia symptoms. Actigraphy will be done at baseline and in the last week of treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Aged 18-65 years.

2. Is capable to give informed consent.

3. Meeting the diagnostic criteria of bipolar depression (including both bipolar I and II disorders) by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), Disorders (SCID-V).

4. a score 20 or above representing current moderate or severe episode of major depression and a score of at least 1 on items H1 or H2 on the Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS), corresponding to at least moderate severity.

5. A score of 41 or less by the Morningness-Eveningness Questionnaire which represents eveningness.

6. On a stable dose of antimanic treatment for bipolar disorder for at least four weeks.

Exclusion Criteria:

1. Major Depressive Disorder fulfilling the Seasonal Pattern Specifier of the DSM-V (Seasonal Affective Disorder).

2. A past history of rapid-cycling within the past twelve months or a Young Mania Rating Scale more than 12 at screening

3. A current or past history of schizophrenia, mental retardation, organic mental disorder; or current substance use disorder.

4. Presence of psychotic symptoms or substantial suicidal risk as judged by the clinician and/or screening instruments.

5. Presence of contraindications to bright light therapy: for example, history of light induced migraine/ epilepsy; current use of photosensitizing medications such as St. John's wart; presence of eye disease: e.g. retinal blindness, severe cataract, glaucoma, and photosensitive skin condition e.g. systemic lupus erythematosus

6. Significant medical condition/ hearing impairment/ speech deficit leading to incapability of completing clinical interview.

7. Regular shift-workers or trans-meridian flight in the past 3 months or during study

8. Enrolment in another clinical trial of an investigational medicinal product or device.

9. Receiving regular psychotherapy.

Related Conditions & MeSH terms

• Bipolar Depression
• Bipolar Disorder
• Depression
• Depressive Disorder

Intervention

Device:
• Bright light therapy
Exposure to 10,000lux bright light for 30minutes a day for six weeks
• Inactive negative ion generator
Exposure to an inactive negative ion generator for 30 minutes a day for six weeks

Locations

Country	Name	City	State
Hong Kong	The Chinese University of Hong Kong	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of depressive symptoms score	Change in the score of the Structural Interview Guide for the Hamilton Depression Rating Scale with atypical depression supplement (SIGH-ADS), SIGH-ADS scores range from 0-79; higher score indicates greater depression severity.	at the end of treatment
Secondary	Change of insomnia symptoms	The change in the score of the Insomnia Severity Index (ISI), which ranges from 0-28, higher score indicates higher severity of insomnia	at the end of treatment